Sugar Substitute Raises Risk of Major Adverse Cardiovascular Events: Daily Dose
Your daily dose of the clinical news you may have missed.
SURMOUNT-OSA: Tirzepatide Improves Sleep Apnea Symptoms, CV Outcomes in Adults with OSA and Obesity
ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.
Global Prevalence of T1D Rising in Older Adults: Daily Dose
CGM Data May Enhance Prediction of Risk for Type 1 Diabetes in Those with Early Stage Disease
ADA 2024. The risk of progression to stage 3 type 1 diabetes may be better predicted using a combination of patient and CGM data, a new study suggests.
Pemvidutide Preserves Lean Mass With Weight Loss of Nearly 16%: MOMENTUM Phase 2 Trial
ADA 2024. MOMENTUM trial findings presented at the ADA yesterday showed 78.1% of weight loss attributable to loss of fat vs lean mass in adults with overweight or obesity.
After ACS, Long-Term Lipid Management for FH Suboptimal in Women Compared to Men
Fiver years after ACS, a new study shows women are less likely to be on lipid lowering therapy and to meet LCL-C target levels than men.
USPSTF Recommends Intensive Behavioral Interventions for Children, Teens with High BMI
The grade B recommendation (moderate certainty) targets youth aged 6 years and older with a BMI at or above the 95th percentile for age and sex.
WHO Issues Medical Product Alert for Counterfeit Semaglutide
Three falsified batches of semaglutide (Ozempic) are in circulation, posing risks for ineffective treatment due to incorrect dosing, contamination, and use of unknown ingredients, warned WHO.
George L Bakris, MD, Expert in Hypertension and Metabolic Disease, Has Died
Described as a giant and a pioneer in the hypertension and metabolic fields, Bakris is also remembered so fondly by colleagues as a very special man.
ADA 84th Scientific Sessions: 3 Studies Primary Care Clinicians Should Put on Their Radar
Details on tirzepatide for obesity-related obstructive sleep apnea, semaglutide for prevention of major kidney outcomes in patients with T2D and CKD, more.
Investigational Influenza-COVID-19 Combination Vaccine Elicits Immune Response in Older Adults: Daily Dose
Chronic Hypertension in Pregnancy Increased Two-Fold Between 2008 and 2021
The doubling of the diagnosis of chronic hypertension in pregnancy was accompanied by no increase in treatment rates, according to a new study.
New Report Shows that Despite Gains, Black Americans Still Face Higher Cardiovascular Mortality
Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.
ADA Standards of Care in Diabetes 2024: A Guideline Topline
For primary care clinicians, this Guideline Topline provides a summary of 2024 ADA Standard of Care updates that may support improved outcomes in your practice.
Dapagliflozin Approved by FDA to Improve Glycemic Control in Children, Adolescents with T2D
Among youth aged 10 to 17 years with uncontrolled hyperglycemia dapagliflozin led to a statistically significant reduction in A1c vs placebo in the T2NOW phase 3 clinical trial.
Can Clinician Empathy Affect Chronic Pain?
A clinician's empathy during a clinic encounter with a person with chronic pain can have a statistically significant impact on outcomes, a new study found.
Investigational RNAi Agent Cuts Triglyceride Levels in Patients with Mixed Hyperlipidemia: Daily Dose
FDA Approves Merck's 21-Valent Pneumococcal Vaccine for Adults 50 Years of Age and Older: A First and Long-Awaited
Capvaxive is the only pneumococcal vaccine formulated specifically to protect adults 50 years and older from IPD and elicited robust immune responses in both vaccine-naïve and vaccine-experienced adults.
Defining Long COVID: Highlights from the National Academy of Sciences Consensus Report
In part the National Academies describe long COVID as "a chronic, systemic disease state with profound consequences." The report provides a working definition.
ADA 84th Scientific Sessions Preview: STEP-HFp-EF Trial Data, Tirzepatide for Obesity-Related OSA, Optimizing Diabetes Care in Primary Care
Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.
